COMMUNIQUÉS West-GlobeNewswire

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
28/02/2024
Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in [...]
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
28/02/2024
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics” or the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and [...]
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
28/02/2024
Proceeds to fully fund first Phase 3 study of cadisegliatin, expected to initiate in mid-2024 HIGH POINT, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical [...]
HealthLynked Welcomes Garrett Gardi to Its Advisory Board
28/02/2024
NAPLES, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a leader in healthcare technology solutions for patients and providers, is thrilled to announce the addition of Garrett Gardi [...]
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results
28/02/2024
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth [...]
Prime Medicine to Participate in Upcoming Investor Conferences
28/02/2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Recludix Pharma to Participate in Two Investor Conferences in March
28/02/2024
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that members of Recludix’s [...]
Spectral AI to Participate in Upcoming Investor Conferences
28/02/2024
DALLAS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
28/02/2024
-- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Plan to initiate TANDEM, pivotal Phase 3 trial evaluating obicetrapib and ezetimibe [...]
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
28/02/2024
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the [...]
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
28/02/2024
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by [...]
Accolade To Present at Upcoming Investor Conferences
28/02/2024
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor conferences: Raymond James 45 th Annual Institutional Investors [...]
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
28/02/2024
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that [...]
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
28/02/2024
CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface PD-1 CTX-8371 provides [...]
Smith+Nephew and U.S. Army Institute of Surgical Research to engage in Master Cooperative Research and Development Agreement
28/02/2024
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced they have entered into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical [...]
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
28/02/2024
Topline results expected in the third quarter of 2024; planning a Phase 2 Trial for prevention of kidney transplant rejection Anti-CD40L has multiple possible indications in addition to solid organ and bone marrow [...]
Mestag Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference
28/02/2024
CAMBRIDGE, United Kingdom, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions to develop impactful treatments for patients, [...]
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
28/02/2024
Obesity, which affects over 1.9 billion people worldwide, is a state of low-grade chronic inflammation that causes an array of different metabolic disorders, including insulin resistance, type 2 Diabetes, hypertension, [...]
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
28/02/2024
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023; increasing commercial [...]

Pages